Form D · Biotechnology
Flame Biosciences, Inc.
New York, NY · CIK 0001806233
Offering snapshot reported Sep 30, 2020 · SEC filing
- Reported sold
- $100M Offering amount: $100M
- Investors reported
- 40 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 28, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 30, 2020 | Initial | $100,000,009 | No comparison | 40 | SEC filing |
| Mar 16, 2020 | Initial | $8,524,243 | No comparison | 58 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-376693
Source: Form D, filed Sep 30, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| George Avgerino | Executive |
| George Avgerinos | Executive |
| David Barrett | Director, Executive |
| Pamela Demain | Executive |
| Leonid Gorelik | Executive |
| Tim Opler | Director |
| Robert Stein | Director |
| Opler Tim | Director |
| Harlan Weisman | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
555 Madison Avenue, Suite 1201
New York, NY, 10022
New York, NY, 10022